Market cap
$10 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-1 Mln
-
ROE
-13.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.2
-
Face value
--
-
Shares outstanding
6,904,500
10 Years Aggregate
CFO
$-278.46 Mln
EBITDA
$-325.04 Mln
Net Profit
$-312.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
| -22.6 | 4.9 | 284.2 | -26.7 | -91.1 | -76.6 | -60.3 |
|
BSE Sensex*
| -11.7 | -2.7 | -8.0 | -8.0 | 6.2 | 7.8 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
| -82.8 | -83.0 | 14.8 | 334.1 | -78.4 | -52.8 |
|
S&P Small-Cap 600
| 13.9 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
1.5 | 10.4 | 21.6 | -15.9 | -33.5 | -- | -- | 1.8 |
| 2.5 | 34.8 | 0.2 | -7.2 | -4,994.9 | -20.7 | -- | 1.1 |
Shareholding Pattern
View DetailsAbout Agile Therapeutics (AGRX)
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination... hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. As of August 26, 2024, Agile Therapeutics, Inc. operates as a subsidiary of Exeltis USA, Inc. Read more
-
Chairman, President & CEO
Mr. Alfred F. Altomari
-
Chairman, President & CEO
Mr. Alfred F. Altomari
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Agile Therapeutics (AGRX)
What is the current share price of Agile Therapeutics Inc (AGRX) Today?
The share price of Agile Therapeutics Inc (AGRX) is $1.51 (NASDAQ) as of 26-Aug-2024 15:20 EDT. Agile Therapeutics Inc (AGRX) has given a return of -91.1% in the last 3 years.
What is the current PB & PE ratio of Agile Therapeutics Inc (AGRX)?
Since, TTM earnings of Agile Therapeutics Inc (AGRX) is negative, P/E ratio is not available.
The P/B ratio of Agile Therapeutics Inc (AGRX) is 1.79 times as on 06-Sep-2024, a 58 discount to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.40
|
-0.35
|
|
2022
|
-0.01
|
-0.03
|
|
2021
|
0.00
|
0.00
|
|
2020
|
0.00
|
0.00
|
|
2019
|
0.00
|
0.00
|
What is the 52 Week High and Low of Agile Therapeutics Inc (AGRX)?
The 52-week high and low of Agile Therapeutics Inc (AGRX) are Rs -- and Rs -- as of 29-May-2026.
What is the market cap of Agile Therapeutics Inc (AGRX)?
Agile Therapeutics Inc (AGRX) has a market capitalisation of $ 10 Mln as on 06-Sep-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Agile Therapeutics Inc (AGRX)?
Before investing in Agile Therapeutics Inc (AGRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.